Literature DB >> 1688596

Protooncogene expression in normal and psoriatic skin.

J T Elder1, A Tavakkol, S B Klein, M E Zeigler, M Wicha, J J Voorhees.   

Abstract

The expression of the c-myc, c-fos, c-jun, c-erbB, and c-Ha-ras protooncogenes was compared by Northern blot analysis of total RNA extracted from keratome biopsies of normal skin and psoriatic plaques. Isolation of intact RNA from frozen tissue required careful attention to technique during the early stages of extraction. Densitometric analysis revealed 1.5- to 2.5-fold elevations of c-myc transcript levels in lesional psoriatic relative to normal epidermis. Similar increases in cyclophilin and lipocortin II transcripts were also observed and may reflect characteristic differences in RNA preparations from normal and psoriatic epidermis. C-myc, c-jun, c-erbB, c-fos, and c-Ha-ras transcript levels were not significantly increased in lesional psoriatic epidermis when protooncogene mRNA levels were normalized to those of the cyclophilin or lipocortin genes. In contrast, transforming growth factor-alpha (TGF-alpha) transcripts were significantly increased (10- to 20-fold) with or without prior normalization. C-myc, c-fos, and c-jun transcripts were significantly induced over in vivo levels 2-4 h after organ culture of normal or psoriatic keratome biopsies, demonstrating that these genes can be highly expressed in the context of tissue injury. Our results suggest that overexpression of these protooncogenes per se is not central to the pathogenesis of psoriatic epidermal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688596     DOI: 10.1111/1523-1747.ep12873313

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  14 in total

1.  Heparin-binding ligands mediate autocrine epidermal growth factor receptor activation In skin organ culture.

Authors:  S Stoll; W Garner; J Elder
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Expression, topography, and function of integrin receptors are severely altered in keratinocytes from involved and uninvolved psoriatic skin.

Authors:  G Pellegrini; M De Luca; G Orecchia; F Balzac; O Cremona; P Savoia; R Cancedda; P C Marchisio
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 3.  Transcription factor regulation of epidermal keratinocyte gene expression.

Authors:  R L Eckert; J F Welter
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

4.  In situ hybridization analysis of cytokine, proto-oncogene and tumour suppressor gene expression in psoriasis.

Authors:  P Schmid; D Cox; G K McMaster; P Itin
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

5.  Immunohistochemical demonstration of c-myc oncogene product in middle ear cholesteatoma.

Authors:  A Holly; M Sittinger; J Bujia
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

6.  Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.

Authors:  H M Ockenfels; G Nussbaum; T Schultewolter; P M Burger; M Goos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

7.  Regulation of fos-lacZ fusion gene expression in primary mouse epidermal keratinocytes isolated from transgenic mice.

Authors:  W B Bollag; Y Xiong; J Ducote; C S Harmon
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

8.  Expression of the carcinoma-associated keratin K6 and the role of AP-1 proto-oncoproteins.

Authors:  F Bernerd; T Magnaldo; I M Freedberg; M Blumenberg
Journal:  Gene Expr       Date:  1993

9.  Vitamin D3 inhibits proliferation and increases c-myc expression in fibroblasts from psoriatic patients.

Authors:  M Casado; M Martin; A Muñoz; J Bernal
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

10.  Role of LIM kinases in normal and psoriatic human epidermis.

Authors:  Masaru Honma; Salvador Aznar Benitah; Fiona M Watt
Journal:  Mol Biol Cell       Date:  2006-02-08       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.